FDA Offers Clarity On Biosimilar Interchangeability

Guidance Provides Draft Q&As On Applications And Labeling

 
• By Dave Wallace

A draft guidance document opened for comment by the FDA offers additional Q&As on issues around biosimilar applications and interchangeability.

FDA entrance sign 2016
The FDA has published further draft Q&As on biosimilars • Source: Shutterstock

More from Biosimilars

More from Products